Home / Peptide legality / South Carolina
Are peptides legal in South Carolina?
South Carolina is restricted: on top of the federal floor, the South Carolina Board of Medical Examiners issued a notice in mid-August 2026 stating that licensed clinicians may not compound, administer, dispense, prescribe, supply, or recommend non-FDA-approved research-grade peptides to patients.
Legal status overview
South Carolina is restricted because it went beyond the federal baseline: the South Carolina Board of Medical Examiners told licensed providers in mid-August 2026 that they may not compound, administer, dispense, prescribe, supply, or recommend non-FDA-approved research-grade peptides, and it extended that limit to advanced practice nurses and physician assistants. The notice added that patient consent forms calling a product research-grade do not reduce professional or legal liability, and that only prescription-quality material may be used in compounding. FDA-approved peptide medicines, such as Wegovy® (semaglutide) and approved somatropin products, remain legal when a licensed provider prescribes them appropriately. Compounded peptides are not FDA-approved, not a generic, and not evaluated by the FDA, and in South Carolina they must use prescription-quality active ingredient through a licensed 503A pharmacy or 503B outsourcing facility.
Key points
- In mid-August 2026 the South Carolina Board of Medical Examiners stated that licensed clinicians may not compound, administer, dispense, prescribe, supply, or recommend non-FDA-approved research-grade peptides to patients. [1]
- The Board extended the restriction to advanced practice nurses and physician assistants, closing the delegation loop so it cannot be bypassed through supervised providers. [1]
- The notice made clear that patient consent forms labeling a product research-grade do not mitigate or eliminate professional or legal liability. [1]
- South Carolina flagged facilities marketing semaglutide salt forms and research-grade powders that are not FDA-approved, and directed that only prescription-quality material be used in compounding. [1]
- FDA-approved peptide drugs, including Wegovy® (semaglutide) and approved somatropin products, remain legal in South Carolina when prescribed by a licensed clinician for an appropriate indication. [3]
- Compounded peptides are not FDA-approved, not a generic, and not evaluated by the FDA; with the GLP-1 shortages resolved, compounding is limited to documented patient-specific need through a licensed pharmacy or outsourcing facility. [2]
- BPC-157 left FDA's Category 2 do-not-compound list in April 2026 but was not moved to the permitted list, so it still cannot be lawfully compounded, and South Carolina's research-grade prohibition reinforces that limit. [5]
- Human growth hormone (somatropin) is further restricted by federal law: distribution for uses the FDA has not authorized is a crime under 21 U.S.C. 333(e), which applies in South Carolina. [6]
Compound-by-compound status
| BPC-157 Restricted | Not on FDA's permitted 503A bulk substances list and captured by South Carolina's research-grade peptide prohibition; not lawfully compoundable for patients in the state today. |
|---|---|
| GLP-1 class (semaglutide, tirzepatide) Restricted | Brand products such as Wegovy® (semaglutide), Ozempic® (semaglutide), and Zepbound® (tirzepatide) are legal by prescription; compounded versions are not FDA-approved, not a generic, and not evaluated by the FDA, and South Carolina requires prescription-quality active ingredient, not research-grade powders or unapproved salt forms. |
| TB-500 (thymosin beta-4) Restricted | No FDA-approved human product and treated as a non-approved research-grade peptide, so it cannot lawfully be compounded, prescribed, or administered to patients in South Carolina. |
| Growth hormone / somatropin Restricted | FDA-approved somatropin is legal by prescription for approved indications only; distribution for non-approved uses is prohibited under federal law 21 U.S.C. 333(e). |
Frequently asked questions
Is BPC-157 legal in South Carolina?
No, not for patient use. It is not on FDA's permitted compounding list, and the South Carolina Board of Medical Examiners' mid-August 2026 notice bars clinicians from compounding, prescribing, or administering non-FDA-approved research-grade peptides, which covers BPC-157. This is information, not legal or medical advice.
Did South Carolina change its peptide rules recently?
Yes. In mid-August 2026 the South Carolina Board of Medical Examiners issued a notice restricting non-FDA-approved research-grade peptides and extended it to advanced practice nurses and physician assistants.
Can I get compounded semaglutide in South Carolina?
Only under narrow conditions. Compounded semaglutide is not FDA-approved, not a generic, and not evaluated by the FDA. The state requires prescription-quality active ingredient, not research-grade powders or unapproved salt forms, and the shortage-era compounding discretion has ended.
Do patient waivers protect a provider who uses research-grade peptides?
No. South Carolina's notice states that consent forms identifying a product as research-grade do not mitigate or eliminate professional or legal liability.
Are FDA-approved peptide medications still legal here?
Yes. Approved products such as Wegovy® (semaglutide) and approved somatropin medicines remain legal in South Carolina when prescribed by a licensed clinician for an appropriate use.
Sources
- What Mississippi And South Carolina Just Said About Research-Grade Peptides (LumaLex Law) (retrieved 2026-09-21)
- FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (retrieved 2026-09-21)
- South Carolina Weight Loss Clinic and Telehealth Compliance Guide (2026), Medical Director Co (retrieved 2026-09-21)
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (FDA) (retrieved 2026-09-21)
- BPC-157 in 2026: Why Regulatory Limbo Is Not the Same as a Green Light (Holt Law) (retrieved 2026-09-21)
- 21 U.S. Code § 333 - Penalties (Legal Information Institute) (retrieved 2026-09-21)
Last researched: 2026-09-21.
FDA recalls from firms in South Carolina
Firms with the most records
Most recent
| Firm | City | Class | Initiated | Reason given |
|---|---|---|---|---|
| Carolina Infusion, LLC | Ridgeland | Class II | 2026-09-10 | Lack of Assurance of Sterility: Related to formulation using bacterios |
A recall here means the FDA recorded a product being withdrawn by a firm with an address in South Carolina. Most involve compounded preparations and the most common reason given is a lack of assurance of sterility. It describes enforcement history, not whether a product is legal to buy in South Carolina. Source: openFDA drug enforcement reports, checked 2026-11-09.
More from Peptides.io
- GLP-1 Treatment Gap Index →Our analysis of where Medicaid access to GLP-1s falls shortest, by state
- The Gray-Market Peptide Report →Our analysis of how unapproved peptides are sold and marketed
- Original research from Peptides.io →Data reports we produce ourselves
Peptide legality in other states
All 50 states are covered. These are the next few alphabetically.
- South Dakotalegal gray zone
- Tennesseelegal gray zone
- Texaslegal gray zone
- Utahlegal gray zone
- Vermontlegal gray zone